Class Action Lawsuit Against Zenas Biopharma, Inc.

Shareholders who purchased Zenas Biopharma's securities in connection with its initial public offering (IPO) on September 13, 2024, may be eligible to participate in a class action lawsuit against the company, alleging false and misleading statements about the company's funded operations and financial projections. The lawsuit claims that Zenas deceptively overstated its financial runway, leading to investor losses. The lawsuit seeks compensation for those who suffered damages as a result of these misrepresentations.

Key Takeaways:

• The class action lawsuit alleges that Zenas Biopharma made false and misleading statements about its funded operations and financial projections in its IPO documents.
• The company allegedly deceptively overstated its financial runway, citing existing cash and expected net proceeds from its IPO.
• Shareholders who purchased Zenas' securities between September 13, 2024, and the present may be eligible to participate in the lawsuit.
• The lawsuit claims that investors suffered damages when the truth about Zenas' financial situation was revealed.
• David J. Schwartz and DJS Law Group are representing the plaintiffs in the lawsuit.

Statistics:

• 14-day average trading volume of Zenas Biopharma's stock hit 647,221 shares, with an average daily trading volume of 84,629 shares between the IPO date and the present.
• The closing price of Zenas Biopharma's stock was $43.58 on September 13, 2024, the day of the IPO.
• The firm's total market capitalization is estimated to be $1.2 billion.

Sources:

• DJS Law Group LLP (press release)
• Zenas Biopharma, Inc. (NASDAQ: ZBIO) (SEC filings)